Dr. Louis Rizio

What is Platelet-Rich Plasma?

Platelet-rich plasma (PRP) is an autologous blood product. It has platelet concentrations higher than whole blood. It is produced by centrifuging whole blood to isolate and concentrate the platelet-rich fraction.[1][2] PRP can be further categorized based on cellular composition, most commonly as leukocyte-rich PRP or leukocyte-poor PRP.[2] The concentration of platelets is crucial in describing a PRP formulation. Another important factor is the method of activation. Additionally, the total number of red blood cells, white blood cells, and neutrophils compared to baseline values are critical characteristics.[1]

Preparation Methods

PRP is prepared by centrifuging a quantity of the patient’s own blood and extracting the active, platelet-rich fraction.[3] The density gradients created during centrifugation can be selectively harvested to obtain different concentrations of various blood product components.[1] Several factors affect the final PRP product. These include the volume of blood aspirated and baseline platelet count. Patient health status and comorbidities also play a role. Additionally, patient medications and anticoagulant choice are important. Centrifugation parameters and the inclusion or exclusion of leukocytes are also considered.[4]

The platelet-rich fraction is then applied to injured tissue, typically by injection.[3] Activation occurs after exposure to connective tissue collagen. Alternatively, it can occur with the addition of a platelet activator such as calcium chloride or thrombin. With activation, 70% to 95% of growth factors are released within 10 minutes. The remainder is slowly released over several days.[2]

Mechanism of Action

PRP exerts its therapeutic effects through multiple biological pathways involving growth factor release, inflammation modulation, and tissue regeneration.[1] Platelet α-granules promote the release of various growth factors. These include vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGF-β).[1][5] These growth factors direct cell proliferation, chemotaxis, and angiogenesis.[4]

Inflammation is modulated through inhibition of the nuclear factor-κB pathway.[1] Following PRP injection for knee osteoarthritis, studies show a significant decrease in protein concentrations of immunoglobulins linked to inflammation. These include apolipoprotein A-I, haptoglobin, immunoglobulin kappa chain, transferrin, and matrix metalloproteinase.[4] Conversely, proteins associated with anti-aging physiological functions increase significantly, including matrilin, transthyretin, and complement 5.[4]

PRP also promotes cartilage regeneration, extracellular matrix remodeling, and enhancement of angiogenesis and synovial tissue repair.[5]

Safety Profile

PRP demonstrates an excellent safety profile with few adverse events reported.[4] A combined analysis of 26 studies (n=1,051) showed non-significant differences in adverse events between PRP and other conservative treatments.[4] The most common adverse events are minor and include temporary pain or swelling at the injection site.[3] As an autologous product, PRP has negligible immunogenicity risk.[6]

Applications and Effectiveness by Condition

Condition	Treatment Type	Reported Treatment Success	References
Knee osteoarthritis	Intra-articular injection	Superior to hyaluronic acid, corticosteroids, and saline for pain and function at 3, 6, and 12 months; improvements in pain, function, and stiffness at 6 months; decreased inflammatory proteins and synovial fluid volume	[1], [2], [3], [4]
Lateral epicondylitis (lateral epicondylitis)	Injection	Positive response demonstrated in multiple RCTs; most robust data supporting PRP for tendinopathy	[1], [5]
Patellar tendinopathy	Injection	Mixed results; no significant difference compared to placebo in some studies	[2], [5], [6]
Achilles tendinopathy	Injection	No difference between PRP and saline injections in well-designed RCTs; no significant difference in pain or function compared to placebo	[2], [5], [7]
Rotator cuff tears	Surgical augmentation (arthroscopic repair)	May augment healing with improved healing rates, reduced pain, and improved functional outcomes, especially in small- to medium-sized tears; substantial analgesic effects; no significant long-term functional difference in pooled data	[1], [5], [6]
Plantar fasciopathy (plantar fasciitis)	Injection	Positive results in RCTs; conflicting evidence with possible benefit; significant improvement in general population, limited data in athletes	[2], [5], [7]
Gluteus medius tendinopathy	Injection	Positive results in RCTs	[5]
Partial hamstring tears	Injection	Substantial promise for treatment	[1]
ACL reconstruction	Surgical augmentation	Studied in multiple trials; specific efficacy data not clearly established	[6]
ACL reconstruction donor graft site	Surgical application	Studied in trials; specific efficacy data not clearly established	[6]
Acute Achilles rupture	Surgical augmentation (repair)	Studied in trials; specific efficacy data not clearly established	[6]
Shoulder impingement syndrome	Surgical augmentation	Studied in trials; specific efficacy data not clearly established	[6]

Key findings across conditions:

PRP demonstrates the strongest evidence for knee osteoarthritis and lateral epicondylitis, with multiple high-quality studies showing superiority over conventional treatments.[1][5][2] Results vary by anatomic location for tendinopathies. Lateral epicondylitis responds well.[5][2] However, Achilles and patellar tendinopathy show inconsistent or negative results.[5][2]

The American Medical Society for Sports Medicine notes that PRP has an excellent safety profile across all applications. There is no significant difference in adverse events compared to other conservative treatments.[3] However, the quality of evidence is generally low to very low due to high risk of bias, study heterogeneity, and inconsistent PRP preparation methods.[6][4]

Important limitations include lack of standardization in PRP preparation, platelet concentration, leukocyte content, and activation methods, making cross-study comparisons challenging.[6][8][9] The clinical significance of positive findings remains debated, as some meta-analyses show statistical but not clinically meaningful improvements.[2]

Would you like me to summarize the current evidence about the optimal PRP preparation techniques (e.g., leukocyte-rich vs. leukocyte-poor, activation techniques, platelet concentration) and their impact on treatment outcomes for specific orthopedic conditions? This could help clarify which protocols yield the best results and tackle the issue of study heterogeneity.

Current Limitations and Challenges

Significant heterogeneity in PRP preparation protocols, formulations, and outcome measures limits direct comparability across studies.[3][7] There is a lack of standardization in platelet and leukocyte content, activation protocols, and injection regimens. Additionally, variations in follow-up durations have contributed to inconsistent results.[3][7] The overall certainty of evidence is rated as moderate by GRADE assessment.[7]

Current clinical practice guidelines stay cautious. The American College of Rheumatology recommends against PRP for knee OA due to very low-certainty evidence. The American Medical Society for Sports Medicine emphasizes the need for responsible use with appropriate patient choice.[8][2]

Future Directions

Standardization of PRP preparation protocols, patient selection criteria, and outcome reporting is essential to improve comparability and guide clinical practice.[3][7] Future research priorities include:

• Establishing consensus protocols for PRP preparation, including optimal platelet concentrations, leukocyte content, and activation methods
• Conducting high-quality, placebo-controlled trials with longer follow-up periods to assess durability of treatment effects
• Exploring combination therapies with other regenerative treatments and innovative delivery systems to enhance therapeutic efficacy[5]
• Developing personalized treatment strategies based on patient characteristics, disease severity, and specific pathology[5]
• Investigating novel therapeutic targets, including approaches targeting fibrosis and senescence[9]
• Determining optimal injection protocols, including number of injections, timing, and volume

The field continues to evolve rapidly. Emerging evidence suggests that optimized, leukocyte-poor PRP formulations may offer the most consistent clinical benefits. These benefits are especially noted for early to moderate osteoarthritis and specific tendinopathies.[7][5]

References

1. Platelet-Rich Plasma: Fundamentals and Clinical Applications. Sheean AJ, Anz AW, Bradley JP. Arthroscopy : The Journal of Arthroscopic & Related Surgery : Official Publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2021;37(9):2732-2734. doi:10.1016/j.arthro.2021.07.003.
2. American Medical Society for Sports Medicine Position Statement: Principles for the Responsible Use of Regenerative Medicine in Sports Medicine. Finnoff JT, Awan TM, Borg-Stein J, et al. Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine. 2021;31(6):530-541. doi:10.1097/JSM.0000000000000973.
3. Platelet-Rich Therapies for Musculoskeletal Soft Tissue Injuries. Moraes VY, Lenza M, Tamaoki MJ, Faloppa F, Belloti JC. The Cochrane Database of Systematic Reviews. 2014;(4):CD010071. doi:10.1002/14651858.CD010071.pub3.
4. Consensus Guidelines on Interventional Therapies for Knee Pain (STEP Guidelines) From the American Society of Pain and Neuroscience. Hunter CW, Deer TR, Jones MR, et al. Journal of Pain Research. 2022;15:2683-2745. doi:10.2147/JPR.S370469.
5. Recent Advances in Platelet-Rich Plasma Therapy for Osteoarthritis: Mechanisms and Clinical Efficacy. Cai L, Chen J, Yuan Q, et al. Journal of Materials Chemistry. B. 2025;. doi:10.1039/d5tb00394f.
6. Platelet-Rich Plasma Therapy in the Treatment of Diseases Associated With Orthopedic Injuries. Fang J, Wang X, Jiang W, et al. Tissue Engineering. Part B, Reviews. 2020;26(6):571-585. doi:10.1089/ten.TEB.2019.0292.
7. Platelet-Rich Plasma for Knee Osteoarthritis: A Comprehensive Narrative Review of the Mechanisms, Preparation Protocols, and Clinical Evidence. Glinkowski WM, Gut G, Śladowski D. Journal of Clinical Medicine. 2025;14(11):3983. doi:10.3390/jcm14113983.
8. Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. Bennell KL, Paterson KL, Metcalf BR, et al. JAMA. 2021;326(20):2021-2030. doi:10.1001/jama.2021.19415.
9. Current State of Platelet-Rich Plasma and Cell-Based Therapies for the Treatment of Osteoarthritis and Tendon and Ligament Injuries. Su CA, Jildeh TR, Vopat ML, et al. The Journal of Bone and Joint Surgery. American Volume. 2022;104(15):1406-1414. doi:10.2106/JBJS.21.01112.

Regenerative Orthopaedics and Sports Medicine NJ

Fill out form below with questions or to schedule

• WordPress
• Instagram